Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

09.03.19

EyeGate Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference

WALTHAM, Mass., September 3, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
08.29.19

EyeGate Pharma Announces Reverse Stock Split Effective August 30, 2019

WALTHAM, MA, August 29, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
08.26.19

EyeGate Pharma Reaches 50% Randomization of Patients in Pivotal Study

WALTHAM, Mass., August 26, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
08.08.19

EyeGate Pharma Reports Second Quarter 2019 Financial Results and Provides Business Update

WALTHAM, MA, August 8, 2019 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced...
Read more
08.05.19

EyeGate Pharma Receives Approval from FDA to Initiate PE Pilot Study

WALTHAM, MA, August 5, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
07.31.19

EyeGate Pharma Announces Randomization of First 25% of Patients in Pivotal Study

WALTHAM, Mass., July 31, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
07.09.19

EyeGate Files FDA Submission to Initiate PE Pilot Study

WALTHAM, Mass., July 9, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
06.26.19

EyeGate Announces First Patient Enrolled in PRK Pivotal Study

WALTHAM, Mass., June 26, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today it has enrolled the first patient in its corneal wound repair pivotal...
Read more